The prevalence of genital HPV and factors associated with oncogenic HPV among men having sex with men and men having sex with women and men: the HIM study
- PMID: 21934568
- PMCID: PMC3178038
- DOI: 10.1097/OLQ.0b013e31822154f9
The prevalence of genital HPV and factors associated with oncogenic HPV among men having sex with men and men having sex with women and men: the HIM study
Abstract
Background: Comparative studies of genital human papillomavirus (HPV) among men having sex with men (MSM), men having sex with women and men (MSWM), and men having sex with women (MSW) have not been conducted so far; however, such comparisons may be important for planning prevention strategies like vaccination.
Methods: Men, aged 18 to 70 years, were enrolled in a study of genital HPV in São Paulo, Brazil; Cuernavaca, Mexico; and Tampa, FL. Men were classified as MSM (n = 170), MSWM (n = 214), and MSW (n = 3326) based on self-reported sexual behavior. Genotyping for HPV was conducted on cells from the penis and scrotum. Prevalence data were adjusted by country. Factors potentially associated with genital HPV were assessed using multivariable Poisson regression.
Results: Genital HPV prevalence was typically higher among MSWM than among MSM or MSW for groups of HPV genotypes including nononcogenic types (51%, 36%, and 42%, respectively), and multiple types (37%, 24%, and 29%, respectively). Age and alcohol consumption in the past month were associated with oncogenic HPV among both MSM and MSWM; however, there were no statistically significant associations between sexual behaviors and genital HPV among MSM or MSWM.
Conclusions: Prevalence of genital HPV may be higher among MSWM than among MSW or MSM. Number of female sex partners was associated with genital HPV among MSW, but number of male anal sex partners was not associated with genital HPV among MSM and MSWM.
Conflict of interest statement
Potential conflicts of interest: A.G.N. receives research funding from Merck & Co. for another study. A.R.G. and L.L.V. are on the speakers’ bureau for Merck and are members of its advisory board. All other authors: no conflict.
Figures
References
-
- IARC. Human papillomaviruses/IARC working group on the evaluation of carcinogenic risks to humans. Vol. 90. Lyon, France: International Agency for Research on Cancer; 2007.
-
- Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent Human papillomavirus vaccine - Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR. 2007;56:1–12. 13–24. - PubMed
-
- FDA licensure of quadrivalent Human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP) MMWR. 2010;59:630–632. - PubMed
-
- Kim JJ. Vaccine policy analyses can benefit from natural history studies of human papillomavirus in men. J Infect Dis. 2007;196:1117–1119. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
